Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $5,640 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $4 |
| Gross Profit | $0 | -$1 | $5,639 | -$4 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $544 | $2,895 | $2,552 | $3,716 |
| G&A Expenses | $1,626 | $2,364 | $1,609 | $1,369 |
| SG&A Expenses | $1,626 | $2,364 | $1,609 | $1,369 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,170 | $5,259 | $4,161 | $5,085 |
| Operating Income | -$2,170 | -$5,259 | $1,479 | -$5,085 |
| % Margin | – | – | 26.2% | – |
| Other Income/Exp. Net | $249 | $121 | $66 | $69 |
| Pre-Tax Income | -$1,921 | -$5,138 | $1,545 | -$5,016 |
| Tax Expense | $0 | $0 | -$1,277 | $0 |
| Net Income | -$1,921 | -$5,138 | $2,822 | -$7,433 |
| % Margin | – | – | 50% | – |
| EPS | -0.16 | -0.42 | 0.27 | -0.78 |
| % Growth | 61.9% | -255.6% | 134.6% | – |
| EPS Diluted | -0.16 | -0.42 | 0.27 | -0.78 |
| Weighted Avg Shares Out | 12,233 | 12,232 | 10,358 | 9,551 |
| Weighted Avg Shares Out Dil | 12,233 | 12,232 | 10,606 | 9,551 |
| Supplemental Information | – | – | – | – |
| Interest Income | $109 | $121 | $66 | $0 |
| Interest Expense | $0 | $0 | $0 | $88 |
| Depreciation & Amortization | $0 | $1 | $1 | $4 |
| EBITDA | -$2,170 | -$5,258 | $1,480 | -$5,081 |
| % Margin | – | – | 26.2% | – |